Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features

Pediatr Blood Cancer. 2013 Oct;60(10):1676-82. doi: 10.1002/pbc.24612. Epub 2013 Jun 1.


Background: Thrombotic thrombocytopenic purpura (TTP) associated with severe, acquired ADAMTS13 deficiency is uncommonly reported in children. The incidence, demographic, and clinical features of these children, compared to adults, have not been described.

Procedures: This study focused on children (<18 years old) and adults with TTP associated with severe, acquired ADAMTS13 deficiency, defined as activity <10%. The incidence rates for TTP in children and adults were calculated from patients enrolled in the Oklahoma TTP-HUS (Hemolytic-Uremic syndrome) Registry, 1996-2012. To describe demographic and clinical features, children with TTP were also identified from a systematic review of published reports and from samples sent to a reference laboratory for analysis of ADAMTS13.

Results: The standardized annual incidence rate of TTP in children was 0.09 × 10(6) children per year, 3% of the incidence rate among adults (2.88 × 10(6) adults per year). Among the 79 children who were identified (one from the Oklahoma Registry, 55 from published reports, 23 from the reference laboratory), TTP appeared to be more common among females, similar to the relative increased frequency of women among adults with TTP, and more common in older children. Clinical data were available on 52 children; the frequency of severe renal failure, relapse, treatment with rituximab, and systemic lupus erythematosus in these children was similar to adults with TTP.

Conclusions: TTP associated with severe, acquired ADAMTS13 deficiency is uncommon in children. The demographic and clinical features of these children are similar to the features of adults with TTP.

Keywords: TTP; children; disparities; incidence; thrombotic thrombocytopenic purpura.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / blood
  • ADAM Proteins / deficiency*
  • ADAMTS13 Protein
  • Adolescent
  • Adult
  • Age Factors
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Incidence
  • Japan / epidemiology
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / diet therapy
  • Lupus Erythematosus, Systemic / epidemiology
  • Male
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / drug therapy
  • Purpura, Thrombotic Thrombocytopenic / epidemiology*
  • Recurrence
  • Registries*
  • Renal Insufficiency / blood
  • Renal Insufficiency / epidemiology
  • Renal Insufficiency / therapy
  • Retrospective Studies
  • Rituximab
  • Sex Factors


  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human